Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial

The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Is the Better Value Option?

Mark Vickery headshot

Top Stock Reports for Johnson & Johnson, Boeing & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Pfizer (PFE).

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $36.30, moving +0.53% from the previous trading session.

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

Lilly Gets FDA Approval for New Oral Tablets for Migraine

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

Kinjel Shah headshot

Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.

Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook

Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

Nektar's Shares Drop on Rating Downgrade by Goldman Sachs

Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.

Pfizer (PFE) Stock Moves -1.1%: What You Should Know

Pfizer (PFE) closed the most recent trading day at $35.44, moving -1.1% from the previous trading session.

Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire

Zoetis (ZTS) names executive vice president Kristin Peck as the new CEO, effective Jan 1, 2020.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.

Merck's Pediatric Filings for Dificid Get FDA's Priority Review

The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.

The Zacks Analyst Blog Highlights: Pfizer, DISH Network, Micron Technology, Walt Disney and C.H. Robinson

The Zacks Analyst Blog Highlights: Pfizer, DISH Network, Micron Technology, Walt Disney and C.H. Robinson

Novartis (NVS) Announces Data on Asthma Drugs & Kisqali

Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.

Mark Vickery headshot

Top Analyst Reports for Pfizer, DISH & Micron

Today's Research Daily features new research reports on 12 major stocks, including Pfizer (PFE), DISH Network (DISH) and Micron Technology (MU).

Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study

AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed at $35.92 in the latest trading session, marking a -0.83% move from the prior day.